On May 15, 2025, Wedbush analyst Robert Driscoll reiterated a "Neutral" rating for Zentalis Pharma (ZNTL, Financial). The analyst maintained the price target for the company at $4.00 USD. This rating and price target remain unchanged from previous assessments.

Zentalis Pharma (ZNTL, Financial), a company listed on the NASDAQ, has seen its price target held steady by Wedbush, reflecting a continued neutral outlook by the analyst. The decision to reiterate the existing rating suggests that Wedbush does not anticipate significant short-term changes in the stock's performance.

Investors and market watchers should note that the reiteration of the "Neutral" rating by the analyst is based on an evaluation of the company's current market position. The maintained price target indicates that no growth or decline is expected in the stock value in the near term, according to the analysis provided.

Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Zentalis Pharmaceuticals Inc (ZNTL, Financial) is $5.97 with a high estimate of $10.00 and a low estimate of $2.20. The average target implies an upside of 407.80% from the current price of $1.18. More detailed estimate data can be found on the Zentalis Pharmaceuticals Inc (ZNTL) Forecast page.

Based on the consensus recommendation from 10 brokerage firms, Zentalis Pharmaceuticals Inc's (ZNTL, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Analyst Reiterates Neutral Rating for Zentalis Pharma (ZNTL) | ZNTL Stock News

Wedbush analyst Robert Driscoll reiterated a 'Neutral' rating for Zentalis Pharma (ZNTL, Financial), maintaining the $4.00 USD price target. The rating reflects a neutral outlook, with no expected short-term stock value changes. The average target price from 9 analysts is $5.97, and the consensus recommendation is 2.4, indicating 'Outperform' status.